Benzinga
Benzinga
Benzinga
mercredi, septembre 30

Connect Biopharma Holdings Ltd

CNTBNASDAQ
Trade with Public
Trade with Public
$1.10
0.1110.89%
À la clôture: Sep 30, 5:00 PM EST
$1.18
0.0756.82%
Après les heures: 5:34 PM EST
PRO
Pourquoi cela bouge-t-il ?:Connect Biopharma shares are trading higher after the company announced pre...
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Connect Biopharma Hldgs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Connect Biopharma Hldgs (CNTB).

Price Target Range — 10 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$6Upside to Avg. PT+443.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 30, 2026BTIGJulian HarrisonPT CutBuy$10→$5
Sep 22, 2026OppenheimerMazahir AlimohamedPT CutOutperform$8→$5
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $5

BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $10 to $5.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Connect Biopharma Hldgs, Lowers Price Target to $5

Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform and lowers the price target from $8 to $5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Connect Biopharma Hldgs, Lowers Price Target to $6

Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lowers the price target from $7 to $6.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target

BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Oppenheimer Initiates Coverage On Connect Biopharma Hldgs with Outperform Rating, Announces Price Target of $8

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $8.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved